149 related articles for article (PubMed ID: 37971239)
21. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
[TBL] [Abstract][Full Text] [Related]
23. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
Alghamdi WA; Alsultan A; Al-Shaer MH; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Schmidt S; Heysell SK; Kempker RR; Cegielski JP; Peloquin CA
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858211
[TBL] [Abstract][Full Text] [Related]
24. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
[TBL] [Abstract][Full Text] [Related]
25. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
27. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
28. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
[TBL] [Abstract][Full Text] [Related]
29. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.
Hwang TJ; Wares DF; Jafarov A; Jakubowiak W; Nunn P; Keshavjee S
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1257-66. PubMed ID: 23735593
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Second-Line Anti-Tubercular Drugs.
Ramachandran G
Indian J Pediatr; 2019 Aug; 86(8):714-716. PubMed ID: 30924070
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P
Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466
[TBL] [Abstract][Full Text] [Related]
32. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
Sasaki T; Svensson EM; Wang X; Wang Y; Hafkin J; Karlsson MO; Mallikaarjun S
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0160821. PubMed ID: 34843388
[TBL] [Abstract][Full Text] [Related]
35. [Comparative clinical electroencephalographic study of cycloserine and terizidon tolerance].
Shmelev NA; Shabalova LN; Kolosovskaia VP
Antibiotiki; 1975 Feb; 20(2):174-80. PubMed ID: 1091207
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
[TBL] [Abstract][Full Text] [Related]
37. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.
Garcia-Prats AJ; Draper HR; Thee S; Dooley KE; McIlleron HM; Seddon JA; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2015 Oct; 59(10):6073-9. PubMed ID: 26195507
[TBL] [Abstract][Full Text] [Related]
39. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
40. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us.
Intini E; Kishore G; Richeldi L; Udwadia ZF
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31806629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
